Send to

Choose Destination
ACS Appl Mater Interfaces. 2019 Mar 20;11(11):10452-10461. doi: 10.1021/acsami.8b18648. Epub 2019 Mar 11.

Fe3O4@ Astragalus Polysaccharide Core-Shell Nanoparticles for Iron Deficiency Anemia Therapy and Magnetic Resonance Imaging in Vivo.

Author information

School of Chinese Medicine , Beijing University of Chinese Medicine , Beijing 100029 , China.
Department of Radiology, Peking Union Medical College Hospital , Chinese Academy of Medical Sciences , Beijing 100730 , China.
Department of Chemistry & Biochemistry , University of California , Santa Cruz , California 95064 , United States.


Iron deficiency anemia (IDA) is a common nutritional disease suffered by 1 billion people. To develop a new drug which avoids the side effects of traditional oral iron supplementation for IDA treatment, we have designed Fe3O4@ Astragalus polysaccharide core-shell nanoparticles (Fe3O4@APS NPs) and demonstrated them to be an efficient therapeutic drug for IDA treatment in vivo. The Fe3O4@APS NPs have been successfully synthesized with good water solubility and stability, especially in imitated digestion. Cytotoxicity assessment in cells and pathological tests in mice justify their good biocompatibility and low toxicity. The IDA treatment in rats shows that they have efficient therapeutic effect, which is contributed to both the iron element supplement from Fe3O4 and the APS-stimulated hematopoietic cell generation. Moreover, the superparamagnetic Fe3O4@APS NPs are capable for use as a magnetic resonance imaging contrast agent. This study presents the possibility of nanocomposites involving purified natural products from Chinese herb medicine for biomedical applications.


Astragalus polysaccharides; Fe3O4 nanoparticles; iron deficiency anemia; magnetic resonance imaging; superparamagnetic


Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center